Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a study of PF-07220060 alone and in combination in advanced solid tumors
2024-512120-11-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of atirmociclib in breast cancer, non-small cell lung cancer (NSCLC), prostate cancer (PCa) and 3 more, sponsored by Pfizer. Planned start Jun 2024; status: authorised.
02
Drugs
atirmociclib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)prostate cancer (PCa)colorectal cancer (CRC)Liposarcoma
Beyond the preview
Go deeper on 2024-512120-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512120-11-00.